Yourgene Health PLC - Manchester-based molecular diagnostics company - Extends strategic partnership with US precision medicine firm Ambry Genetics, for a new Genomic Services collaboration. The partnership will give both firms access to each other's technology and assays.
In June 2021, Yourgene first signed a deal with Ambry to give access to Yourgene's Noninvasive prenatal testing technology.
"This is a multi-level partnership with a leader in the field of precision medicine. Ambry will provide an addressable US market for NIPT and a range of class leading oncology products and services to bring to our recently expanded UK based genomic services footprint. We very much look forward to strengthening and broadening our relationship with Ambry, cementing our relationship with this prestigious US company," says Chief Executive Officer Lyn Rees.
Current stock price: 9.90 pence
12-month change: down 31%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
